RCEL Stock Analysis: Buy, Sell, or Hold?
RCEL - Avita Medical, Inc. Common Stock
$3.95
0.00 (0.06%)
▲
5d:
-20.95%
30d:
-0.44%
90d:
-19.5%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When RCEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RCEL is down 20.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RCEL is down 20.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RCEL is currently trading at $3.95, which is considered slightly low relative to its 30-day fair value range of $3.83 to $4.58. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.7) compared to its historical average (8.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, RCEL is showing sideways momentum. The price is currently testing key support at $3.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: RCEL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.02 (+128.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RCEL is showing sideways momentum. The price is currently testing key support at $3.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: RCEL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.02 (+128.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.83 -
$4.58
Company Quality Score
49/100
(HOLD)
Options IV Signal
34th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
63.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 34th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 128.5% below Wall St target ($9.02)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to -20.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$3.83 -
$4.58
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.91
(22.9%)
Support & Resistance Levels
Support Level
$3.95
Resistance Level
$4.55
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.68
Wall Street Target
$9.02
(+128.5%)
Revenue Growth (YoY)
4.0%
Profit Margin
-62.7%
PE vs Historical
-4.7 vs 8.0
CHEAP
Share & Embed Analysis
Last updated: July 14, 2026 10:41 AM ET
Data refreshes hourly during market hours. Next update: 11:41 AM
Data refreshes hourly during market hours. Next update: 11:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RCEL showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David D O'toole
BUY
3000 shares
2026-02-19
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$74 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$97 | 67 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$116 | 59 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$239 | 57 HOLD |
